Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Coya Therapeutics, Inc. Common Stock

COYA

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.

Last trade $3.01
Day change +$0.01 (+0.33%)
Day range $2.92 – $3.16
Volume 85,770
Market cap $70M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$70.37M
Price / earnings
—
Price / book
2.1×
Price / sales
15.01×
EV / sales
7.37×
EV / EBITDA
-1.09×

Profitability

Earnings per share
-$1.29
Return on assets
-76.74%
Return on equity
-89.88%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.24×
Quick ratio
7.24×
Cash ratio
6.64×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.83M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for COYA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$234.13K$243.75K$251.15K$3.96M$3.56M$163.62K$257.88K$1.95K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$234.13K$243.75K$251.15K$3.96M$3.56M$163.62K$257.88K$1.95K
Selling, general and administrative$2.59M$2.26M$3.78M$3.27M$2.56M$2.91M$2.71M$2.14M
Research and development$8.59M$5.03M$4.11M$6.71M$3.43M$3.66M$5.21M$1.94M
Total operating expenses$11.18M$7.29M$7.89M$9.99M$6M$6.58M$7.93M$4.08M
Operating income-$10.95M-$7.05M-$7.64M-$6.03M-$2.43M-$6.41M-$7.68M-$4.08M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$10.62M-$6.64M-$7.21M-$5.71M-$2.12M-$6.09M-$7.31M-$3.64M
Income taxes$0$0$0$3.09K$0$0$0-$720.29K
Net income-$10.62M-$6.64M-$7.21M-$5.71M-$2.12M-$6.09M-$7.31M-$2.92M
Net income attributable to common shareholders-$10.62M-$6.64M-$7.21M-$5.71M-$2.12M-$6.09M-$7.31M-$2.92M
EBITDA-$10.95M-$7.04M-$7.64M-$6.02M-$2.43M-$6.41M-$7.67M-$4.07M
Basic earnings per share-$0.45-$0.28-$0.32-$0.34-$0.13-$0.36-$0.44-$0.18
Diluted earnings per share-$0.45-$0.28-$0.32-$0.34-$0.13-$0.36-$0.44-$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

$32 Million Exosome Therapy Market Assessment 2026: Set to Experience Massive Growth, Reaching $1.4 Billion by 2040

The global exosome therapy market is projected to grow from $32 million in 2026 to $1.4 billion by 2040, with a CAGR of 41.1%. Key growth drivers include expanding clinical pipelines, increased regulatory filings, and rising investment in regenerative medicine. Ophthalmology and oncology represent major therapeutic areas, while Asia-Pacific is positioned as a leading market. However, challenges include inconsistent therapeutic preparations, contamination risks, and quality control complexities.

Benzinga

Analyst Expectations for Coya Therapeutics's Future

Within the last quarter, Coya Therapeutics (NASDAQ:COYA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 4 0 0 0 0 According to 8 analyst offering 12-month price targets in the last 3 months, Coya Therapeutics has an average price target of $19.75 with a high of $28.00 and a low of $9.00. Below is a summary of how these ...Full story available on Benzinga.com

Benzinga

The Latest Analyst Ratings for Coya Therapeutics

Coya Therapeutics (NASDAQ:COYA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 9 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 5 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 These 9 analysts have an average price target of $18.33 versus the current price of Coya Therapeutics at $4.715, implying upside. Below is a summary of how these 9 analysts rated Coya Therapeutics over ...Full story available on Benzinga.com

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.